

Pau Riera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3867683/publications.pdf>

Version: 2024-02-01

20
papers

183
citations

1163117

8
h-index

1125743

13
g-index

20
all docs

20
docs citations

20
times ranked

371
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. <i>British Journal of Cancer</i> , 2019, 120, 190-195.	6.4	31
2	Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. <i>Angiogenesis</i> , 2019, 22, 433-440.	7.2	28
3	Targeted Next-Generation Sequencing in a Large Cohort of Genetically Undiagnosed Patients with Neuromuscular Disorders in Spain. <i>Genes</i> , 2020, 11, 539.	2.4	25
4	Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3044-3057.	7.0	23
5	Relevance of <i>CYP3A4*20</i> , <i>UGT1A1*37</i> and <i>UGT1A1*28</i> variants in irinotecan-induced severe toxicity. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1389-1392.	2.4	19
6	ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 973.	3.5	14
7	Physicochemical Compatibility of Amiodarone with Parenteral Nutrition. <i>Journal of Parenteral and Enteral Nutrition</i> , 2019, 43, 298-304.	2.6	9
8	Physicochemical Stability and Sterility of Standard Parenteral Nutrition Solutions and Simulated Y-site Admixtures for Neonates. <i>Nutrition in Clinical Practice</i> , 2018, 33, 694-700.	2.4	8
9	Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer. <i>Pharmacogenomics Journal</i> , 2018, 18, 556-564.	2.0	7
10	A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 725-730.	2.1	6
11	Physicochemical Compatibility of Dexmedetomidine With Parenteral Nutrition. <i>Nutrition in Clinical Practice</i> , 2020, 35, 967-972.	2.4	5
12	Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1157-1163.	3.3	5
13	Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients. <i>Cancers</i> , 2020, 12, 2245.	3.7	2
14	Relevancia de la variante <i>CYP3A4*20</i> como predictor de neuropatía inducida por paclitaxel en población española. <i>Medicina Clínica</i> , 2018, 150, 163-164.	0.6	1
15	Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype. <i>Annals of Oncology</i> , 2017, 28, iii12.	1.2	0
16	Prognostic factors and specific populations in the pharmacogenetic randomized phase II trial of FOLFIRI with high-dose (HD) of irinotecan vs standard doses in metastatic colorectal cancer (mCRC) patients (pts) according to UGT1A1 genotype. <i>Annals of Oncology</i> , 2017, 28, v180.	1.2	0
17	Relevance of the <i>CYP3A4*20</i> variant as a predictor of paclitaxel-induced neuropathy in the Spanish population. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 163-164.	0.2	0
18	Physicochemical compatibility of dexmedetomidine with total parenteral nutrition. <i>Clinical Nutrition</i> , 2018, 37, S312-S313.	5.0	0

#	ARTICLE	IF	CITATIONS
19	Comments on: "Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan". Pharmacological Research, 2019, 145, 104287.	7.1	0
20	Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients.. Farmacia Hospitalaria, 2021, 45, 5-10.	0.6	0